Humabs BioMed has opened a new research laboratory in Bellinzona. According to a press release, the new construction covers an area of 500 square meters in the Business Center in Bellinzona. The laboratory also features office space of the same surface area. The new location will have space for more than 50 employees to work.
Humabs BioMed conducts research into active agents to treat infectious diseases and has developed, among other things, an antibody to combat the Ebola virus. The firm was hived off from the Institute for Research in Biomedicine in Bellinzona in 2004. In 2017, it was taken over by the US corporation Vir Biotechnology. Following the takeover, Vir Biotechnology not only decided to retain the headquarters of Humabs BioMed in Ticino, but also invested heavily in the new location. This is according to Filippo Riva, General Director of Humabs BioMed, who also comments: “We are proud to have consolidated our presence in Bellinzona, a town that over the years has strengthened its position as an international center of scientific research”.
Moreover, Riva claims that the new location should help strengthen research lines and accelerate development.